Foundation Medicine, Inc.

Ucl Business Plc

Genentech, Inc.

Vanderbilt University

Philip James Stephens

Roman Yelensky

Doron Lipson

Matthew J Hawryluk

Garrett Michael Frampton

Alexander Nevin Parker

Vincent A Miller

Sean R Downing

Jeffrey S Ross

Geoffrey Alan Otto

Matthias Alexander Lechner

Mikhail G Shapiro

Chris Hendrik Boshoff

Timothy Robert Fenton

James Xin Sun

Gary Palmer

David Fabrizio

Siraj Mahamed Ali

Priti Hegde

Jie He

Maureen T Cronin

Mima Jarosz

Mirna Jarosz

Sanjeev Mariathasan

Richard Bourgon

Gregg Fine

Alexander N Parker

Marcin Kowanetz

David Shames

Douglas B Johnson

Michael Pellini

Christine Marie Lovly

Jeffrey Alan Sosman

Wei Zou

Helena Futscher De Deus

Rachel Lauren Erbach

Ronald David Collette

Mary Pat Lancelotta

Eric Karl Neumann

Caitlin F Connelly

Zachary R Chalmers

Garrett Michaell Frampton

Priti Hedge

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

Therapeutic and diagnostic methods for cancer

Methods and compositions for treating cholangiocarcinoma.

Methods of treating cholangiocarcinoma

Novel RET fusion molecules and uses are disclosed.

KIF5B-RET fusion molecules and uses thereof

A method of analyzing a tumor sample comprising:

Optimization of multigene analysis of tumor samples

Novel mutant ESR1 molecules and uses are disclosed.

Estrogen receptor mutations and uses thereof

Methods of treating a head and neck cancer are disclosed.

Human papilloma virus as predictor of cancer prognosis

Methods and compositions for treating cancer such as melanomas are disclosed.

Methods of treating cancer

Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

NTRK1 fusion molecules and uses thereof

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. According to one aspect, a graph-based data model is used that may be used to organizes and revise precision medicine knowledge. In one example structure, gene states are abstracted into alteration groups, where alteration groups are built using reverse engineering actionable information and storing that information within the graph-based data structure. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system in a graph-based data format. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act. According to other aspects, curated information is provided on the system to enable practitioners to make informed decisions regarding the implications of the presence of specific genomic alterations.

System and method for managing genomic information

Growing community of inventors

Lexington, MA, United States of America

Philip James Stephens